How to appeal a UnitedHealthcare adult car-t cell therapy denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

UnitedHealthcare-specific note: UHC's parent UnitedHealth Group owns Optum (PBM Optum Rx) and Surest. Surest plans have different cost-sharing rules. State complaints flow to state insurance department + DOL/EBSA for self-funded.

What UnitedHealthcare's policy requires for adult car-t cell therapy

Cited policy: UnitedHealthcare Commercial Medical Benefit Drug Policy — Axicabtagene Ciloleucel (Yescarta)

FDA-approved indication: r/r LBCL after 1L chemoimmunotherapy with primary-refractory disease or relapse <=12 mo (Apr 2022 2L expansion) OR r/r LBCL 3L+ (Oct 2017) OR r/r FL 3L+ (Mar 2021). Patient age >=18. ECOG 0-2. Adequate organ function: ANC >=1000, plt >=75K, LVEF >=45%, CrCl >=60, AST/ALT <2.5x ULN, total bili <2.0. Administered at FACT-accredited REMS-certified authorized treatment center. Lymphodepletion Flu 30 mg/m² + Cy 500 mg/m² days -5/-4/-3 covered as part of episode.

How UnitedHealthcare denies adult car-t cell therapy — and how to counter it

Where UnitedHealthcare pushes back: 1) 'Try auto-HSCT first' for 2L; 2) 'Investigational' framing; 3) Out-of-state ATC denied; 4) Bridging chemotherapy bundled denial; 5) ECOG 2 deemed ineligible.

Counter-arguments that hold up: ZUMA-7 (Locke NEJM 2022;386:640) — Yescarta beat SOC chemo + auto-HSCT in 2L primary-refractory/early-relapse DLBCL with EFS HR 0.40 — this is the basis for FDA Apr 1 2022 2L approval and NCCN B-cell Lymphomas v6.2024 preferred 2L pathway. CMS NCD 110.24 (Aug 7 2019) covers FDA-approved indications — 'investigational' is non-compliant. ASTCT 2024 consensus + REMS require FACT-accredited ATC; if no in-network ATC, SCA + travel coverage required under ACA network-adequacy rules. Bridging is inherent to CAR-T pathway per NCCN. Pasquini Blood Adv 2024 CIBMTR registry — ECOG 2 outcomes comparable to ITT.

What UnitedHealthcare typically denies for adult car-t cell therapy

Across UnitedHealthcare's commercial and Medicare books, denials cluster around a small number of patterns. For adult car-t cell therapy, expect:

• GLP-1 weight-loss exclusion
• Out-of-network reduction citing UCR
• Step therapy on biologics
• Prior auth denied for advanced imaging
• Quantity limits on specialty drugs

Treatments most often denied in this category

These are the adult car-t cell therapy treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Yescarta
• Kymriah
• Tecartus
• Breyanzi
• Carvykti
• Abecma

How to submit the appeal to UnitedHealthcare

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document UnitedHealthcare cited in the denial.
3. File the appeal through UnitedHealthcare's portal (members: https://www.myuhc.com ; providers: https://www.uhcprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MN, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See UnitedHealthcare's prior-authorization criteria by drug: UnitedHealthcare PA criteria on ApprovalHelp.